e-learning
resources
Munich 2014
Monday, 08.09.2014
Bronchodilators for asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: The SPARK study
J. A. Wedzicha, A. D'Urzo, K. Mezzi, H. Chen, D. Banerji, R. Fogel (London, United Kingdom; Toronto, Canada; Basel, Switzerland; East Hanover, United States Of America)
Source:
International Congress 2014 – Bronchodilators for asthma and COPD
Session:
Bronchodilators for asthma and COPD
Session type:
Oral Presentation
Number:
1893
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. A. Wedzicha, A. D'Urzo, K. Mezzi, H. Chen, D. Banerji, R. Fogel (London, United Kingdom; Toronto, Canada; Basel, Switzerland; East Hanover, United States Of America). QVA149 showed significant improvements in lung function and health status and was well tolerated versus glycopyrronium and tiotropium in patients with severe COPD: The SPARK study. Eur Respir J 2014; 44: Suppl. 58, 1893
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Once-daily QVA149 provides superior improvements in lung function compared with glycopyrronium and tiotropium in severe COPD patients: A 52 week pooled analysis
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Once-daily QVA149 improves lung function and dyspnoea compared with tiotropium plus formoterol: The QUANTIFY study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Patients with severe COPD show significant improvements in dyspnea and lung function with once-daily QVA149: The BLAZE study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015
LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study
Source: International Congress 2014 – Latest insights in airway diseases
Year: 2014
Safety of once-daily glycopyrronium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Free triple combination of glycopyrronium, indacaterol and ICS improves lung function and dyspnoea versus free double combination of indacaterol and ICS in patients with COPD: A post-hoc analysis from the GLOW6 study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Dual bronchodilation with once-daily QVA149 improves dyspnea and health status and reduces symptoms and rescue medication use in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Effect of glycopyrronium vs tiotropium on pulmonary function and morning symptoms in patients with moderate-to-severe COPD: The SPRING study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
QVA149 improves lung function and reduces exacerbations compared to tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept